Literature DB >> 30601374

Optimal Timing for Trichomonas vaginalis Test of Cure Using Nucleic Acid Amplification Testing.

Megan Clare Craig-Kuhn, Charleigh Granade, Christina A Muzny1, Barbara Van Der Pol1, Rebecca Lillis2, Stephanie N Taylor2, Norine Schmidt, David H Martin, Patricia Kissinger.   

Abstract

BACKGROUND: The optimal timing for nucleic acid amplification testing (NAAT) posttreatment for Trichomonas vaginalis has not been fully established. Testing too soon posttreatment may detect remnant nucleic acid that is not from viable organisms, falsely misclassifying person as infected. The purpose of this study was to examine how long T. vaginalis nucleic acid is detectable postmetronidazole (MTZ) treatment.
METHODS: Women diagnosed with T. vaginalis treated with MTZ (2 g single-dose or 500 mg twice daily for 7 days multidose) self-collected a vaginal swab for NAAT at baseline and each week postcompletion of treatment through test of cure (TOC) at week 4, when a culture was also performed. Women who reported interim sexual exposure or who were culture positive at 4 weeks were excluded. Time to first negative NAAT was examined using Kaplan Meier analysis.
RESULTS: All women receiving multidose metronidazole were NAAT-negative by 21 days and those receiving single dose by 28 days postcompletion of treatment. Though over half (60.7%) of the cohort reinitiated sex during follow-up¸ all reported using condoms during sex or that they and their partner were treated before sex. Six (6.7%) of 89 had a positive NAAT following their first negative NAAT.
CONCLUSIONS: The optimal timing for T. vaginalis retesting after completion of treatment is 3 weeks for those receiving multidose MTZ and 4 weeks for those receiving single-dose, though sexual reexposure and false negatives should be considered.

Entities:  

Year:  2019        PMID: 30601374      PMCID: PMC6465101          DOI: 10.1097/OLQ.0000000000000968

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  25 in total

1.  A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.

Authors:  Patricia Kissinger; Leandro Mena; Judy Levison; Rebecca A Clark; Megan Gatski; Harold Henderson; Norine Schmidt; Susan L Rosenthal; Leann Myers; David H Martin
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

2.  Persistent, undetected Trichomonas vaginalis infections?

Authors:  Thomas A Peterman; Lin H Tian; Carol A Metcalf; C Kevin Malotte; Sindy M Paul; John M Douglas
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

3.  Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial.

Authors:  Jane R Schwebke; Marcia M Hobbs; Stephanie N Taylor; Arlene C Sena; Michael G Catania; Barbara S Weinbaum; Ann D Johnson; Damon K Getman; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2011-09-21       Impact factor: 5.948

4.  Detection of Trichomonas vaginalis DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system.

Authors:  Barbara Van Der Pol; James A Williams; Stephanie N Taylor; Catherine L Cammarata; Charles A Rivers; Barbara A Body; Melinda Nye; Deanna Fuller; Jane R Schwebke; Mathilda Barnes; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2014-01-03       Impact factor: 5.948

5.  The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study.

Authors:  M R Spence; T S Harwell; M C Davies; J L Smith
Journal:  Obstet Gynecol       Date:  1997-05       Impact factor: 7.661

6.  Application of computer-assisted interviews to sexual behavior research.

Authors:  P Kissinger; J Rice; T Farley; S Trim; K Jewitt; V Margavio; D H Martin
Journal:  Am J Epidemiol       Date:  1999-05-15       Impact factor: 4.897

7.  Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition.

Authors:  R Scott McClelland; Laura Sangare; Wisal M Hassan; Ludo Lavreys; Kishorchandra Mandaliya; James Kiarie; Jeckoniah Ndinya-Achola; Walter Jaoko; Jared M Baeten
Journal:  J Infect Dis       Date:  2007-01-22       Impact factor: 5.226

8.  Observation of probable persistent, undetected Trichomonas vaginalis infection among HIV-positive women.

Authors:  Megan Gatski; Patricia Kissinger
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

9.  Rapid Diagnosis of Trichomonas vaginalis by Testing Vaginal Swabs in an Isothermal Helicase-Dependent AmpliVue Assay.

Authors:  Charlotte A Gaydos; Marcia Hobbs; Jeanne Marrazzo; Jane Schwebke; Jenell S Coleman; Billie Masek; Laura Dize; Dan Jang; Jenny Li; Max Chernesky
Journal:  Sex Transm Dis       Date:  2016-06       Impact factor: 2.830

Review 10.  Trichomoniasis and HIV interactions: a review.

Authors:  Patricia Kissinger; Alys Adamski
Journal:  Sex Transm Infect       Date:  2013-04-20       Impact factor: 3.519

View more
  4 in total

Review 1.  Management of Resistant Trichomoniasis.

Authors:  Cynthia Alessio; Paul Nyirjesy
Journal:  Curr Infect Dis Rep       Date:  2019-08-06       Impact factor: 3.725

2.  Diagnosis and Management of Trichomonas vaginalis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines.

Authors:  Patricia J Kissinger; Charlotte A Gaydos; Arlene C Seña; R Scott McClelland; David Soper; W Evan Secor; Davey Legendre; Kimberly A Workowski; Christina A Muzny
Journal:  Clin Infect Dis       Date:  2022-04-13       Impact factor: 20.999

3.  Clinical Validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas Vaginitis Assays: Results from a Prospective Multicenter Clinical Study.

Authors:  Jane R Schwebke; Stephanie N Taylor; Ronald Ackerman; Robert Schlaberg; Neil B Quigley; Charlotte A Gaydos; Steven E Chavoustie; Paul Nyirjesy; Carmelle V Remillard; Philip Estes; Byron McKinney; Damon K Getman; Craig Clark
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

4.  Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study.

Authors:  Christina A Muzny; Jane R Schwebke; Paul Nyirjesy; Gregory Kaufman; Leandro A Mena; Gweneth B Lazenby; Olivia T Van Gerwen; Keonte J Graves; Janeen Arbuckle; Belvia A Carter; Connette P McMahon; Scott Eder; Jackie Shaw; Brajesh Pandey; Steven E Chavoustie
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.